First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients

Indian Journal of Medical and Paediatric Oncology

Volumn 33, Issue 3, 2012, Pages 146-154

  Louis, Robert A ^a   Rajendranath, Rejiv ^a   Ganesan, Prasanth ^a   Sagar, T G ^a   Krishnamurthy, Arvind ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Gefitinib; Non small cell lung cancer; Non smokers; South India

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; DIARRHEA; DRUG CHOICE; FATIGUE; FEMALE; HUMAN; INDIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEX DIFFERENCE; SMOKING; TREATMENT OUTCOME; VOMITING;

EID: 84870200577     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.103141     Document Type: Article

References (21)

1. Swaminathan R, Shanta V, Balasubramanian S. Cancer incidence and mortality in Chennai, India: 2006-2008. National Cancer Registry Program, Cancer Institute (WIA), Chennai, 2010.
2. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed). American College of Chest Physicians. Chest 2007;132(3 Suppl):29S-55S.
3. Subramanian J, Govindan R. Lung cancer in never smokers: A review. J Clin Oncol 2007;10;25: 561-70.
4. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007;36: 1048-59.
5. Heigener DF. Non-small cell lung cancer in never-smokers: A new disease entity? Onkologie 2011;34: 202-7.
6. Behera D, Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci 2004;46: 269-81.
7. Shajeem O, Behera D, Aggarwal AN. Chemotherapy versus best supportive care in the management of lung cancer. J Assoc Physicians India 2003;51: 261-4.
8. Rajappa S, Gundeti S, Talluri MR, Digumarti R. Chemotherapy for advanced lung cancer: A 5-year experience. Indian J Cancer 2008;45: 20-6.
9. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. American Society of Clinical Oncology. J Clin Oncol 2009;27: 6251-66.
10. NCCN Guidelines on Non-Small Cell Lung Cancer, version 3.2011. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp,http:// www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. [Last Accessed on 2011 May].
11. Parikh P, Chang AY, Nag S, Digumarti R, Bhattacharyya GS, Doval DC, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol 2008;3: 380-5.
12. Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1: 847-55.
13. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-37.
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-57.
15. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-8.
16. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-8.
17. Zhou C, Wu YL, Chen G, Feng JF, Liu X, Wang C, et al. On behalf of the OPTIMAL investigators: Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut) advanced non-small cell lung cancer (NSCLC).Abstract 7520 ASCO 2011. Available from: http://chicago2011.asco.org/ Abstracts.aspx. [Last Accessed on 2011 June 1].
18. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. Spanish Lung Cancer Group: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Abstract 7503 ASCO 2011. Available from: http://chicago2011.asco.org/Abstracts.aspx. [Last Accessed on 2011 June 1].
19. Yang CH, Fukuoka M, Mok TS, Wu YL, Thongprasert S, Saijo N, et al. Final overall survival results from a phase III randomized, open-label, first-line study of gefitinib V carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia. 35th ESMO Congress. Abstract LBA2. Presented October 11, 2010. Available from: http://www.esmo.org/events/milan- 2010- congress.html. [Last Accessed on 2011 June 1].
20. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. North-East Japan Study Group. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Abstract 7519 ASCO 2011, Available from: http://chicago2011. asco.org/Abstracts.aspx. [Last Accessed on 2011 June 1].
21. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011;73: 316-9.